Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

January 19, 2022

Study Completion Date

April 13, 2022

Conditions
SARS-CoV-2
Interventions
DRUG

Alisporivir

Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).

OTHER

Standard of care (SOC)

Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)

Trial Locations (1)

Unknown

Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil

Sponsors
All Listed Sponsors
collaborator

Debiopharm International SA

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER